Cancer Care Is Becoming a Corporate Cost Problem

For American companies, cancer is no longer only a health issue affecting individual employees and their families. It is increasingly a balance-sheet consideration. Cancer has ranked as the leading condition driving employer healthcare costs for four consecutive years, according to Business Group on Health, with 88% of surveyed employers identifying it among their three largest cost drivers in 2025.

The development matters because employer-sponsored insurance is one of the central pillars of the U.S. healthcare system. When the cost of treating serious illness rises, the financial effects can extend beyond insurers and hospitals. They can influence corporate benefit budgets, employee compensation, productivity and decisions about how companies structure healthcare coverage.

The pressure is arriving at a time when overall employer healthcare costs are already rising rapidly. Aon expects U.S. employer healthcare costs to increase 9.5% in 2027, before cost-mitigation measures, with the increase driven increasingly by the amount and type of care being used rather than simply by general inflation.

Why cancer is such a difficult cost to manage

Cancer is not a single treatment or expense. Care can involve screening, diagnostic testing, surgery, radiation, chemotherapy, immunotherapy, targeted medicines, hospital care and long-term monitoring. Costs vary substantially depending on the cancer type, stage, treatment and where care is delivered.

That complexity makes cancer particularly difficult for employers to manage through conventional insurance-plan adjustments. Cutting utilization indiscriminately could reduce spending, but it could also interfere with clinically appropriate treatment. The more useful question for employers is therefore whether they can improve the value of care rather than simply reduce the amount of care.

The National Cancer Institute describes cancer as one of the most expensive medical conditions to treat in the United States. It notes that patients increasingly receive costly chemotherapy, biologic medicines and other newer treatments compared with a decade ago. National cancer-attributable medical care costs were estimated at $208.9 billion in 2020, and the NCI expects costs to increase as the population ages and more expensive treatments become standard care.

At the same time, the number of Americans living with cancer is substantial. The NCI estimated more than two million new cancer cases in the United States in 2025. More people surviving cancer also means more people potentially requiring continuing surveillance, treatment and supportive care.

The economics of expensive innovation

One of the central tensions is that rising cancer costs are partly a consequence of medical progress.

New therapies can offer patients additional treatment options and, in some cases, meaningful improvements in survival or quality of life. But those innovations can also introduce treatments that are considerably more expensive than older approaches.

For employers, this creates a difficult purchasing decision. A benefit plan must be prepared for relatively uncommon but potentially very expensive cases. A single complex cancer episode can involve multiple providers and therapies over an extended period, making aggregate costs sensitive to the severity and timing of individual cases.

That is why cancer costs behave differently from many ordinary healthcare expenses. An employer can estimate the cost of routine physician visits relatively easily. Predicting the financial impact of a workforce experiencing a cluster of serious cancer cases is considerably harder.

Employers are moving toward value rather than simple cost cutting

The response is increasingly focused on where and how cancer care is delivered.

Business Group on Health says employers are expanding cancer prevention and screening strategies while paying greater attention to access to high-value treatment. About half of employers surveyed planned to offer a cancer center-of-excellence program in 2026, while another 23% were considering doing so by 2028.

The logic is straightforward. If patients can be directed toward providers and treatment centers with stronger outcomes or more appropriate care pathways, employers may be able to improve clinical results while reducing unnecessary spending.

This approach also reflects the limits of traditional insurance design. Higher deductibles can shift some costs from employers to employees, but they do not necessarily reduce the underlying price of cancer treatment. Better provider selection, earlier diagnosis and coordinated treatment potentially address the cost of care itself.

Aon similarly identifies navigation to appropriate care, utilization management and strategies focused on price, utilization and the mix of care as important tools for employers confronting higher healthcare costs.

The burden extends beyond the healthcare budget

Cancer can affect companies through more than insurance claims.

Treatment may require extended time away from work, reduced working capacity or adjustments to an employee's schedule. Family members can also become caregivers, creating additional pressure on attendance and productivity.

For employees, the financial consequences can be significant even when insurance covers much of the treatment. The National Cancer Institute notes that cancer patients and survivors face a heightened risk of financial hardship, with costs potentially including deductibles, copayments, coinsurance, medicines, travel and other expenses associated with treatment.

This creates a complicated corporate incentive. Employers have an interest in controlling healthcare costs, but they also have an interest in keeping employees healthy, financially secure and able to remain productive. Aggressive cost shifting may lower an employer's immediate expenditure while creating other costs elsewhere.

For multinational companies, the issue can become even broader. Business Group on Health reported that 67% of multinational employers surveyed said rising U.S. healthcare costs affected the benefits they offer globally. Cancer was also identified as a major healthcare cost concern outside the United States.

What comes next

The direction of cancer-related employer spending will depend on several competing forces.

Medical innovation could continue to introduce highly effective but expensive treatments. At the same time, better screening, earlier diagnosis, improved care coordination and more precise treatment could reduce the severity and cost of some cases. Changes in drug pricing, insurance negotiations and provider competition could also influence the economics.

Employers are unlikely to have a single solution. Instead, cancer benefits are likely to become more targeted, with greater emphasis on prevention, early detection, specialist navigation and treatment at high-performing centers.

The larger significance is that cancer illustrates a broader transformation in corporate healthcare economics. Employers are no longer dealing simply with rising prices for a fixed basket of medical services. They are managing a system in which demographics, disease prevalence, medical innovation and treatment complexity interact.

For businesses, the challenge will be to distinguish between spending that merely increases costs and spending that produces better health outcomes. As cancer care becomes more sophisticated—and more expensive—that distinction could become one of the most consequential questions in the future of employer-sponsored healthcare.